L773:1476 5381
Search: L773:1476 5381 > Animal modeling of ...
- 28 of 196
- Previous record
- Next record
- To hitlist
- Marklund, NiklasUppsala universitet,Neurokirurgi (author)
Animal modeling of traumatic brain injury in pre-clinical drug development : where do we go from here?
- Article/chapterEnglish2011
Publisher, publication year, extent ...
- 2012-02-09
- Wiley,2011
- printrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:uu-146230
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-146230URI
- https://doi.org/10.1111/j.1476-5381.2010.01163.xDOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Traumatic brain injury (TBI) is the leading cause of death and disability in young adults. Survivors of TBI frequently suffer from long term personality changes and deficits in cognitive and motor performance, urgently calling for novel pharmacological treatment options. To date, all clinical trials evaluating neuroprotective compounds have failed in demonstrating clinical efficacy in cohorts of severely injured TBI patients. The purpose of the present review is to describe the utility of animal models of TBI for pre-clinical evaluation of pharmacological compounds. No single animal model can adequately mimic all aspects of human TBI owing to the heterogeneity of clinical TBI. To successfully develop compounds for clinical TBI, a thorough evaluation in several TBI models and injury severities is crucial. Additionally, brain pharmacokinetics and the time window must be carefully evaluated. Although the search for a single-compound, "silver bullet" therapy is ongoing, a combination of drugs targeting various aspects of neuroprotection, neuroinflammation and regeneration may be needed. In summary, finding drugs and prove clinical efficacy in TBI is a major challenge ahead for the research community and the drug industry. For a successful translation of basic science knowledge to the clinic to occur we believe that a further refinement of animal models and functional outcome methods is important. In the clinical setting, improved patient classification, more homogenous patient cohorts in clinical trials, standardized treatment strategies, improved CNS drug delivery systems and monitoring of target drug levels and drug effects is warranted.
Subject headings and genre
- MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Kirurgi hsv//swe
- MEDICAL AND HEALTH SCIENCES Clinical Medicine Surgery hsv//eng
- Traumatic brain injury
- review
- neuroprotection
- magnesium
- yclosporin
- glutamate
- reactive oxygen species
- inflammation
- plasticity
- animal modeling
- contusion
- Neurosurgery
- Neurokirurgi
- Neurosurgery
- Neurokirurgi
Added entries (persons, corporate bodies, meetings, titles ...)
- Hillered, LarsUppsala universitet,Neurokirurgi(Swepub:uu)larshill (author)
- Uppsala universitetNeurokirurgi (creator_code:org_t)
Related titles
- In:British Journal of Pharmacology: Wiley164:4, s. 1207-12290007-11881476-5381
Internet link
Find in a library
- British Journal of Pharmacology (Search for host publication in LIBRIS)
To the university's database
- 28 of 196
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Marklund, Niklas
- Hillered, Lars
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Surgery
- Articles in the publication
- British Journal ...
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
